Varian Medical (NYSE:VAR), known for its use of rfxcel serialization software , said today it launched an FDA-cleared version of its Velocity cancer imaging software, including a new Rapidsphere module.
The newly launched Velocity 4.0’s Rapidsphere module is designed for Y90 selective internal radiation therapy dosimetry analysis and provides improved information on tumor responses and normal-tissue toxicity for patients undergoing SIRT, the Palo Alto, Calif.-based company said.
The Velocity 4.0 software includes the company’s Velocity M3i multi-modality motion imaging component, the Velocity Aria sync component and the Velocity tumor & dose tracking component.
“At Varian, we are focused on providing clinicians with powerful and comprehensive solutions that enable them to provide personalized cancer therapy for patients. Patient-specific 3D imaging and dosimetry for targeted cancer therapy delivery is important for predicting the tumor’s response to therapy. The Rapidsphere module is a significant advancement for interventional radiologists performing Y90 SIRT,” Varian oncology systems biz prez Kolleen Kennedy said in a press release.